|Bid||0.0000 x 3000|
|Ask||0.0000 x 3000|
|Day's Range||1.8600 - 1.9300|
|52 Week Range||0.7800 - 4.5600|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Citius Pharmaceuticals (NASDAQ: CTXR) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should.
Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. ("Citrus" or the "Company") (NASDAQ: CTXR). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
NEW YORK, NY / ACCESSWIRE / July 7, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Citius Pharmaceuticals, Inc. ('Citius' or 'the Company') (NASDAQ:CTXR).